

Barney S Graham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1490995/publications.pdf>

Version: 2024-02-01

422
papers

68,944
citations

1461

110
h-index

1213

234
g-index

467
all docs

467
docs citations

467
times ranked

63157
citing authors

#	ARTICLE	IF	CITATIONS
1	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
2	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
3	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 383-391.	15.2	65
4	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. <i>Nature Medicine</i> , 2022, 28, 373-382.	15.2	16
5	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	6.0	119
6	Structure-based design of stabilized recombinant influenza neuraminidase tetramers. <i>Nature Communications</i> , 2022, 13, 1825.	5.8	21
7	Functional reconstitution of the MERS CoV receptor binding motif. <i>Molecular Immunology</i> , 2022, 145, 3-16.	1.0	2
8	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. <i>Nature Medicine</i> , 2022, 28, 1022-1030.	15.2	34
9	Recurrent respiratory syncytial virus infection in a CD14 deficient patient. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	5
10	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	2.9	287
11	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , 2022, 48, 101477.	3.2	13
12	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	7
13	Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. <i>The Lancet Healthy Longevity</i> , 2022, 3, e405-e416.	2.0	9
14	Next-Generation Influenza Vaccines. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038448.	2.9	23
15	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
16	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 80-82.	13.9	665
17	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 184-192.	2.3	6
18	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. <i>Vaccines</i> , 2021, 9, 73.	2.1	24

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
20	Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients. <i>Frontiers in Immunology</i> , 2021, 12, 615102.	2.2	15
21	Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses. <i>Journal of Clinical Immunology</i> , 2021, 41, 906-913.	2.0	133
22	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
23	A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. <i>Nature Communications</i> , 2021, 12, 1722.	5.8	41
24	Quadrivalent influenza nanoparticle vaccines induce broad protection. <i>Nature</i> , 2021, 592, 623-628.	13.7	180
25	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904
26	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347
27	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021, 54, 769-780.e6.	6.6	37
28	Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 1468-1470.	13.9	417
29	SARS-CoV-2 Viral Variantsâ€”Tackling a Moving Target. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1261.	3.8	165
30	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1â€”Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2021, 224, 1916-1924.	1.9	27
31	Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2021, 39, 3053-3066.	1.7	66
32	Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans. <i>Journal of Infectious Diseases</i> , 2021, 224, 1550-1555.	1.9	5
33	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. <i>Frontiers in Immunology</i> , 2021, 12, 662909.	2.2	0
34	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021, 2, 100313.	3.3	56
35	SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. <i>Annals of Internal Medicine</i> , 2021, 174, 687-690.	2.0	64
36	Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. <i>Emerging Infectious Diseases</i> , 2021, 27, 1-9.	2.0	20

#	ARTICLE	IF	CITATIONS
37	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2259-2261.	13.9	603
38	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. <i>Science Immunology</i> , 2021, 6, .	5.6	34
39	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
40	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
41	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
42	Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. <i>International Journal of Infectious Diseases</i> , 2021, 109, 56-62.	1.5	7
43	Attenuated activation of pulmonary immune cells in mRNA-1273â€“vaccinated hamsters after SARS-CoV-2 infection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
44	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. <i>Immunity</i> , 2021, 54, 1869-1882.e6.	6.6	59
45	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
46	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
47	Durability of mRNA-1273 vaccineâ€“induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	6.0	459
48	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.	6.0	244
49	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
50	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1111-1120.	5.2	38
51	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€“boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
52	Stabilized coronavirus spike stem elicits a broadly protective antibody. <i>Cell Reports</i> , 2021, 37, 109929.	2.9	64
53	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <i>Vaccine</i> , 2021, 39, 7394-7400.	1.7	63
54	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 772864.	2.2	21

#	ARTICLE	IF	CITATIONS
55	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, 628-636.	1.9	38
56	Vaccination Against Respiratory Syncytial Virus. , 2020, , 665-676.		0
57	Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. <i>Journal of Virology</i> , 2020, 94, .	1.5	162
58	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. <i>New England Journal of Medicine</i> , 2020, 383, 2427-2438.	13.9	1,242
59	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	13.7	1,153
60	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020, 33, 108322.	2.9	59
61	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	13.7	705
62	An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. <i>New England Journal of Medicine</i> , 2020, 383, 1920-1931.	13.9	2,719
63	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020, 6, eaba5068.	4.7	50
64	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
65	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. <i>Scientific Reports</i> , 2020, 10, 18149.	1.6	90
66	An R848-Conjugated Influenza Virus Vaccine Elicits Robust Immunoglobulin G to Hemagglutinin Stem in a Newborn Nonhuman Primate Model. <i>Journal of Infectious Diseases</i> , 2020, 224, 351-359.	1.9	14
67	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. <i>Cell</i> , 2020, 181, 1004-1015.e15.	13.5	506
68	Rapid COVID-19 vaccine development. <i>Science</i> , 2020, 368, 945-946.	6.0	623
69	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. <i>PLoS ONE</i> , 2020, 15, e0232757.	1.1	11
70	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. <i>Frontiers in Immunology</i> , 2020, 11, 842.	2.2	36
71	Broad neutralization of SARS-related viruses by human monoclonal antibodies. <i>Science</i> , 2020, 369, 731-736.	6.0	534
72	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30

#	ARTICLE	IF	CITATIONS
73	Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. <i>Nature Communications</i> , 2020, 11, 791.	5.8	36
74	Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. <i>Science</i> , 2020, 367, 1260-1263.	6.0	7,517
75	Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. <i>PLoS ONE</i> , 2020, 15, e0228572.	1.1	13
76	Next-generation influenza vaccines: opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 239-252.	21.5	192
77	Effect of a Chikungunya Virusâ€œLike Particle Vaccine on Safety and Tolerability Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1369.	3.8	68
78	Consensus summary report for CEPI/BC March 12â€œ13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. <i>Vaccine</i> , 2020, 38, 4783-4791.	1.7	102
79	Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. <i>JCI Insight</i> , 2020, 5, .	2.3	13
80	Prototype pathogen approach for pandemic preparedness: world on fire. <i>Journal of Clinical Investigation</i> , 2020, 130, 3348-3349.	3.9	33
81	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. <i>ELife</i> , 2020, 9, .	2.8	123
82	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>SSRN Electronic Journal</i> , 2020, , 3639618.	0.4	3
83	Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. <i>Journal of Infectious Diseases</i> , 2019, 219, 59-67.	1.9	42
84	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019, 365, 505-509.	6.0	207
85	Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. <i>Immunity</i> , 2019, 51, 398-410.e5.	6.6	107
86	Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice. <i>Journal of Infectious Diseases</i> , 2019, 220, 1577-1588.	1.9	39
87	Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. <i>Immunity</i> , 2019, 51, 429-442.	6.6	99
88	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. <i>Lancet HIV</i> , the, 2019, 6, e667-e679.	2.1	67
89	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. <i>PLoS ONE</i> , 2019, 14, e0222178.	1.1	18
90	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019, 37, 6208-6220.	1.7	16

#	ARTICLE	IF	CITATIONS
91	Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. <i>Cell Reports</i> , 2019, 28, 3395-3405.e6.	2.9	63
92	Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. <i>Immunity</i> , 2019, 51, 735-749.e8.	6.6	71
93	Structure-Based Vaccine Antigen Design. <i>Annual Review of Medicine</i> , 2019, 70, 91-104.	5.0	160
94	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet</i> , The, 2019, 393, 889-898.	6.3	99
95	Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine. <i>Journal of Infectious Diseases</i> , 2019, 219, S107-S109.	1.9	12
96	A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus. <i>Virology</i> , 2019, 534, 1-13.	1.1	9
97	Fc Glycan-Mediated Regulation of Placental Antibody Transfer. <i>Cell</i> , 2019, 178, 202-215.e14.	13.5	157
98	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e297-e306.	2.1	73
99	Immunological goals for respiratory syncytial virus vaccine development. <i>Current Opinion in Immunology</i> , 2019, 59, 57-64.	2.4	28
100	Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins. <i>MSphere</i> , 2019, 4, .	1.3	18
101	Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas. <i>Viruses</i> , 2019, 11, 212.	1.5	75
102	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. <i>MBio</i> , 2019, 10, .	1.8	88
103	Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	0.9	37
104	Epitope-Specific Serological Assays for RSV: Conformation Matters. <i>Vaccines</i> , 2019, 7, 23.	2.1	26
105	A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer Fc γ 3R-mediated protection against heterologous lethal influenza virus infection. <i>International Immunology</i> , 2019, 31, 81-90.	1.8	12
106	Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. <i>PLoS Biology</i> , 2019, 17, e3000164.	2.6	26
107	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. <i>Nature Immunology</i> , 2019, 20, 362-372.	7.0	211
108	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	18

#	ARTICLE	IF	CITATIONS
109	DNA vaccination before conception protects Zika virus-exposed pregnant macaques against prolonged viremia and improves fetal outcomes. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	31
110	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. <i>Cell</i> , 2019, 179, 1636-1646.e15.	13.5	219
111	Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization. <i>Journal of Virology</i> , 2019, 93, .	1.5	111
112	A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry. <i>Journal of Virological Methods</i> , 2019, 265, 77-83.	1.0	12
113	A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells. <i>Journal of Immunology</i> , 2019, 202, 1250-1264.	0.4	34
114	Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. <i>Nature Microbiology</i> , 2019, 4, 124-133.	5.9	40
115	Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. <i>Vaccine</i> , 2019, 37, 7394-7395.	1.7	46
116	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	3.9	95
117	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. <i>Pathogens and Immunity</i> , 2019, 4, 294.	1.4	26
118	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018, 92, .	1.5	155
119	A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. <i>Journal of Infectious Diseases</i> , 2018, 218, 347-354.	1.9	333
120	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. <i>ACS Infectious Diseases</i> , 2018, 4, 788-796.	1.8	65
121	Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. <i>Immunity</i> , 2018, 48, 339-349.e5.	6.6	126
122	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	1.9	32
123	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. <i>Nature Biotechnology</i> , 2018, 36, 152-155.	9.4	109
124	The Zika virus envelope protein glycan loop regulates virion antigenicity. <i>Virology</i> , 2018, 515, 191-202.	1.1	49
125	Novel Vaccine Technologies. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1431.	3.8	73
126	Is It Possible to Develop a Universal Influenza Virus Vaccine?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029413.	2.3	34

#	ARTICLE	IF	CITATIONS
127	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. <i>Lancet, The</i> , 2018, 391, 552-562.	6.3	235
128	Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. <i>Nature Immunology</i> , 2018, 19, 20-28.	7.0	110
129	Human Respiratory Syncytial Virus. , 2018, , .		1
130	Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge. <i>PLoS ONE</i> , 2018, 13, e0205071.	1.1	18
131	DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0206837.	1.1	24
132	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. <i>Scientific Reports</i> , 2018, 8, 15701.	1.6	408
133	The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography. <i>Viruses</i> , 2018, 10, 446.	1.5	69
134	Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus. <i>Frontiers in Immunology</i> , 2018, 9, 1861.	2.2	31
135	Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera. <i>Scientific Reports</i> , 2018, 8, 8628.	1.6	28
136	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. <i>PLoS Medicine</i> , 2018, 15, e1002493.	3.9	174
137	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. <i>Lancet Infectious Diseases, The</i> , 2018, 18, e295-e311.	4.6	355
138	Zika Virus. , 2018, , 1266-1267.e1.		0
139	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	13.9	314
140	Chimpanzee Adenovirus Vector Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 928-938.	13.9	243
141	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , 2017, 543, 248-251.	13.7	699
142	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2711-2716.	3.3	201
143	Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. <i>Nature Communications</i> , 2017, 8, 14158.	5.8	58
144	Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses. <i>Clinical Nuclear Medicine</i> , 2017, 42, 329-334.	0.7	63

#	ARTICLE	IF	CITATIONS
145	Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virus-Specific CD8+ T Cell Immunodominance Hierarchy in Neonates. <i>Journal of Immunology</i> , 2017, 198, 394-403.	0.4	20
146	Vaccine development for respiratory syncytial virus. <i>Current Opinion in Virology</i> , 2017, 23, 107-112.	2.6	133
147	Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater <i>In Vivo</i> Protection than the Murine Precursor of Palivizumab. <i>Journal of Virology</i> , 2017, 91, .	1.5	24
148	Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vected-Vaccine Candidate. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
149	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1376-1385.	1.9	59
150	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. <i>Journal of Virology</i> , 2017, 91, .	1.5	148
151	Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. <i>Science Immunology</i> , 2017, 2, .	5.6	84
152	Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F. <i>Journal of Virology</i> , 2017, 91, .	1.5	15
153	A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. <i>Nature Communications</i> , 2017, 8, 676.	5.8	125
154	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	20
155	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7348-E7357.	3.3	944
156	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. <i>Nature Communications</i> , 2017, 8, 1877.	5.8	53
157	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. <i>Npj Vaccines</i> , 2017, 2, 15.	2.9	24
158	Recent progress in immune-based interventions to prevent HIV-1 transmission to children. <i>Journal of the International AIDS Society</i> , 2017, 20, e25038.	1.2	8
159	Zika Virus Vaccine Development. <i>Journal of Infectious Diseases</i> , 2017, 216, S957-S963.	1.9	38
160	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
161	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	3.9	104
162	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	1.1	27

#	ARTICLE	IF	CITATIONS
163	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS ONE, 2017, 12, e0186854.	1.1	42
164	Phenotype and Hierarchy of Two Transgenic T Cell Lines Targeting the Respiratory Syncytial Virus KdM282-90 Epitope Is Transfer Dose-Dependent. PLoS ONE, 2016, 11, e0146781.	1.1	4
165	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). PLoS ONE, 2016, 11, e0166393.	1.1	14
166	A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology. PLoS Pathogens, 2016, 12, e1005486.	2.1	18
167	Vaccines for Emerging Viral Diseases. , 2016, , 543-560.		1
168	Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Science Immunology, 2016, 1, .	5.6	180
169	A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nature Communications, 2016, 7, 13916.	5.8	81
170	Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus. Journal of Infectious Diseases, 2016, 214, S497-S499.	1.9	33
171	Chikungunya in the Americas: Recommendations and Conclusions. Journal of Infectious Diseases, 2016, 214, S510-S513.	1.9	7
172	Pre-fusion structure of a human coronavirus spike protein. Nature, 2016, 531, 118-121.	13.7	623
173	Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7â€“9th Sep 2015. Vaccine, 2016, 34, 2865-2869.	1.7	43
174	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	15.2	313
175	Vaccines against respiratory syncytial virus: The time has finally come. Vaccine, 2016, 34, 3535-3541.	1.7	77
176	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjugate Chemistry, 2016, 27, 2372-2385.	1.8	44
177	Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection. Journal of Allergy and Clinical Immunology, 2016, 138, 1477-1480.e5.	1.5	9
178	Zika Virus: Immunity and Vaccine Development. Cell, 2016, 167, 625-631.	13.5	113
179	Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. Journal of Virology, 2016, 90, 10022-10038.	1.5	31
180	Rapid development of a DNA vaccine for Zika virus. Science, 2016, 354, 237-240.	6.0	348

#	ARTICLE	IF	CITATIONS
181	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 811-820.	3.6	110
182	Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. <i>Cell Reports</i> , 2016, 16, 1485-1491.	2.9	190
183	Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. <i>Vaccine</i> , 2016, 34, 4843-4849.	1.7	49
184	A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. <i>Journal of Infectious Diseases</i> , 2016, 214, 1487-1491.	1.9	51
185	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016, 166, 609-623.	13.5	270
186	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , 2016, 375, 2037-2050.	13.9	391
187	Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses. <i>ACS Biomaterials Science and Engineering</i> , 2016, 2, 2324-2332.	2.6	50
188	Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. <i>Scientific Reports</i> , 2016, 6, 34108.	1.6	106
189	Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. <i>Cell</i> , 2016, 167, 684-694.e9.	13.5	141
190	A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. <i>Journal of Virology</i> , 2016, 90, 7508-7518.	1.5	40
191	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	13.9	295
192	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. <i>Nature Medicine</i> , 2016, 22, 362-368.	15.2	163
193	Determinants of early life immune responses to RSV infection. <i>Current Opinion in Virology</i> , 2016, 16, 151-157.	2.6	40
194	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 31-42.	4.6	187
195	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016, 351, 1339-1342.	6.0	370
196	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. <i>Science</i> , 2016, 351, 1343-1346.	6.0	176
197	Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 311-320.	4.6	133
198	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	1.9	28

#	ARTICLE	IF	CITATIONS
199	Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2016, 11, e0159709.	1.1	27
200	History of passive antibody administration for prevention and treatment of infectious diseases. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 129-134.	1.5	114
201	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. <i>Journal of AIDS & Clinical Research</i> , 2015, 06, .	0.5	17
202	DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0125914.	1.1	17
203	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2015, 10, e0128779.	1.1	38
204	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	1.1	23
205	Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. <i>PLoS Pathogens</i> , 2015, 11, e1005035.	2.1	106
206	Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults. <i>PLoS ONE</i> , 2015, 10, e0123969.	1.1	22
207	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, 319ra206.	5.8	390
208	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. <i>Lancet, The</i> , 2015, 385, 1545-1554.	6.3	109
209	HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians. <i>Vaccine</i> , 2015, 33, 1243-1249.	1.7	32
210	Evaluation of candidate vaccine approaches for MERS-CoV. <i>Nature Communications</i> , 2015, 6, 7712.	5.8	258
211	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	6.0	191
212	H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. <i>Journal of Immunology</i> , 2015, 195, 602-610.	0.4	83
213	Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. <i>Journal of Virology</i> , 2015, 89, 9499-9510.	1.5	58
214	Novel antigens for RSV vaccines. <i>Current Opinion in Immunology</i> , 2015, 35, 30-38.	2.4	102
215	Chimpanzee Adenovirus Vector Ebola Vaccine – Preliminary Report. <i>New England Journal of Medicine</i> , 2015, 373, 775-776.	13.9	147
216	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. <i>Cell</i> , 2015, 162, 1090-1100.	13.5	278

#	ARTICLE	IF	CITATIONS
217	Prefusion Fâ€™specific antibodies determine the magnitude of RSV neutralizing activity in human sera. <i>Science Translational Medicine</i> , 2015, 7, 309ra162.	5.8	312
218	Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. <i>Contemporary Clinical Trials</i> , 2015, 44, 112-118.	0.8	12
219	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. <i>Nature Medicine</i> , 2015, 21, 1065-1070.	15.2	567
220	Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BNâ€™ FILO in healthy UK adults. <i>Journal of Infection</i> , 2015, 71, 688.	1.7	0
221	Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial. <i>Journal of Infectious Diseases</i> , 2015, 211, 549-557.	1.9	108
222	Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles. <i>PLoS ONE</i> , 2015, 10, e0120797.	1.1	43
223	Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011). <i>PLoS ONE</i> , 2014, 9, e91366.	1.1	23
224	Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e106240.	1.1	5
225	Protecting the Family to Protect the Child: Vaccination Strategy Guided by RSV Transmission Dynamics. <i>Journal of Infectious Diseases</i> , 2014, 209, 1679-1681.	1.9	22
226	Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3446-3454.	1.4	50
227	Quantitative and Qualitative Deficits in Neonatal Lung-Migratory Dendritic Cells Impact the Generation of the CD8+ T Cell Response. <i>PLoS Pathogens</i> , 2014, 10, e1003934.	2.1	78
228	HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission. <i>PLoS Medicine</i> , 2014, 11, e1001616.	3.9	29
229	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. <i>Journal of Immunology</i> , 2014, 193, 6172-6183.	0.4	34
230	Clonotypeâ€™specific avidity influences the dynamics and hierarchy of virusâ€™specific regulatory and effector ^{CD}4⁺ ^T cell responses. <i>European Journal of Immunology</i> , 2014, 44, 1058-1068.	1.6	14
231	Structural Analysis of Respiratory Syncytial Virus Reveals the Position of M2-1 between the Matrix Protein and the Ribonucleoprotein Complex. <i>Journal of Virology</i> , 2014, 88, 7602-7617.	1.5	100
232	Progress with PfSPZ Vaccine, a radiation attenuated <i>Plasmodium falciparum</i> sporozoite vaccine. <i>Malaria Journal</i> , 2014, 13, .	0.8	0
233	Proof of principle for epitope-focused vaccine design. <i>Nature</i> , 2014, 507, 201-206.	13.7	451
234	No Increase in Activated T Cells and Limited Increase in Adenovirus-specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A48-A48.	0.5	0

#	ARTICLE	IF	CITATIONS
235	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	1.5	248
236	CD8 ⁺ T-cell Mediated HIV Inhibition after Vaccination with a DNA/Recombinant Ad5 (rAd5) HIV Vaccine Is Similar to that Seen in Treated HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A84-A84.	0.5	1
237	The Immune Space: A Concept and Template for Rationalizing Vaccine Development. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1017-1022.	0.5	11
238	Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. <i>Journal of Virology</i> , 2014, 88, 4047-4057.	1.5	220
239	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2014, 384, 2046-2052.	6.3	206
240	Genetic Vaccine for Respiratory Syncytial Virus Provides Protection Without Disease Potentiation. <i>Molecular Therapy</i> , 2014, 22, 196-205.	3.7	35
241	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 4843-4856.	3.9	25
242	CD8 ⁺ TCR Transgenic Strains Expressing Public versus Private TCR Targeting the Respiratory Syncytial Virus KdM282 ⁹⁰ Epitope Demonstrate Similar Functional Profiles. <i>PLoS ONE</i> , 2014, 9, e99249.	1.1	7
243	Advances in antiviral vaccine development. <i>Immunological Reviews</i> , 2013, 255, 230-242.	2.8	83
244	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. <i>Science</i> , 2013, 341, 1359-1365.	6.0	686
245	Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. <i>Science</i> , 2013, 340, 1113-1117.	6.0	656
246	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
247	Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4 ⁺ T cells. <i>European Journal of Immunology</i> , 2013, 43, 3197-3208.	1.6	19
248	Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>Science</i> , 2013, 342, 592-598.	6.0	797
249	VRC 311: Phase I Clinical Trial of a Virus-Like Particle Chikungunya Vaccine in Healthy Adults. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB330.	1.5	0
250	DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Interval-Dependent Manner in Adults. <i>Journal of Infectious Diseases</i> , 2013, 208, 413-417.	1.9	49
251	Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect. <i>Journal of Infectious Diseases</i> , 2013, 208, 418-422.	1.9	117
252	HIV-1 Vaccine-Induced T-Cell Responses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. <i>PLoS Pathogens</i> , 2013, 9, e1003404.	2.1	39

#	ARTICLE	IF	CITATIONS
253	Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire. <i>Journal of Infectious Diseases</i> , 2013, 207, 1829-1840.	1.9	52
254	Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2013, 372, 391-404.	0.7	48
255	Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease. <i>Current Topics in Microbiology and Immunology</i> , 2013, 372, 3-38.	0.7	193
256	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e59340.	1.1	71
257	Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering Simian Immunodeficiency Virus DNA. <i>Journal of Immunology</i> , 2012, 188, 714-723.	0.4	30
258	Respiratory Syncytial Virus Glycoprotein G Interacts with DC-SIGN and L-SIGN To Activate ERK1 and ERK2. <i>Journal of Virology</i> , 2012, 86, 1339-1347.	1.5	71
259	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 630-638.	1.4	4
260	Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. <i>Journal of Clinical Investigation</i> , 2012, 122, 4606-4620.	3.9	120
261	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. <i>Journal of Infectious Diseases</i> , 2011, 203, 1396-1404.	1.9	138
262	Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01. <i>Journal of Virology</i> , 2011, 85, 8954-8967.	1.5	209
263	Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus. <i>Journal of Molecular Biology</i> , 2011, 409, 853-866.	2.0	100
264	Tribute to David T. Karzon, MD and Robert M. Chanock, MD. <i>Vaccine</i> , 2011, 29, 3725-3727.	1.7	0
265	Whither monkeypox vaccination. <i>Vaccine</i> , 2011, 29, D60-D64.	1.7	32
266	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 916-924.	4.6	174
267	Primary Human mDC1, mDC2, and pDC Dendritic Cells Are Differentially Infected and Activated by Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2011, 6, e16458.	1.1	61
268	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	1.1	131
269	GM-CSF Production Allows the Identification of Immunoprevalent Antigens Recognized by Human CD4+ T Cells Following Smallpox Vaccination. <i>PLoS ONE</i> , 2011, 6, e24091.	1.1	16
270	Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial. <i>PLoS ONE</i> , 2011, 6, e24517.	1.1	39

#	ARTICLE	IF	CITATIONS
271	Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. <i>Immunological Reviews</i> , 2011, 239, 149-166.	2.8	196
272	The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. <i>Nature Reviews Immunology</i> , 2011, 11, 65-70.	10.6	41
273	Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects. <i>Journal of Infectious Diseases</i> , 2011, 204, 1541-1549.	1.9	23
274	T Cell Receptor Clonotype Influences Epitope Hierarchy in the CD8+ T Cell Response to Respiratory Syncytial Virus Infection. <i>Journal of Biological Chemistry</i> , 2011, 286, 4829-4841.	1.6	29
275	Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes. <i>Journal of Virology</i> , 2011, 85, 7788-7796.	1.5	327
276	HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable. <i>Journal of Immunology</i> , 2011, 187, 3391-3401.	0.4	54
277	Neonatal CD8 T-cell Hierarchy Is Distinct from Adults and Is Influenced by Intrinsic T cell Properties in Respiratory Syncytial Virus Infected Mice. <i>PLoS Pathogens</i> , 2011, 7, e1002377.	2.1	68
278	Future Opportunities for Passive Immunity Against Viral Diseases. <i>Journal of Infectious Diseases</i> , 2011, 204, 1648-1650.	1.9	0
279	Structural basis of respiratory syncytial virus neutralization by motavizumab. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 248-250.	3.6	156
280	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. <i>PLoS ONE</i> , 2010, 5, e9015.	1.1	125
281	Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection. <i>PLoS ONE</i> , 2010, 5, e10555.	1.1	64
282	Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity. <i>PLoS ONE</i> , 2010, 5, e11995.	1.1	57
283	Responses against a Subdominant CD8+ T Cell Epitope Protect against Immunopathology Caused by a Dominant Epitope. <i>Journal of Immunology</i> , 2010, 185, 4673-4680.	0.4	46
284	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. <i>Journal of Virology</i> , 2010, 84, 630-638.	1.5	57
285	A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-1 Uninfected East Africans (RV 172). <i>Journal of Infectious Diseases</i> , 2010, 201, 600-607.	1.9	100
286	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. <i>Journal of Virology</i> , 2010, 84, 4998-5006.	1.5	110
287	Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16262-16267.	3.3	580
288	Epitope-Specific Regulatory CD4 T Cells Reduce Virus-Induced Illness while Preserving CD8 T-Cell Effector Function at the Site of Infection. <i>Journal of Virology</i> , 2010, 84, 10501-10509.	1.5	24

#	ARTICLE	IF	CITATIONS
289	Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F. <i>Journal of Virology</i> , 2010, 84, 12236-12244.	1.5	105
290	Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa. <i>PLoS ONE</i> , 2010, 5, e12873.	1.1	86
291	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). <i>PLoS ONE</i> , 2010, 5, e13579.	1.1	47
292	Evidence of Prior Exposure to Human Bocavirus as Determined by a Retrospective Serological Study of 404 Serum Samples from Adults in the United States. <i>Vaccine Journal</i> , 2009, 16, 597-604.	3.2	21
293	Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials. <i>Journal of Virology</i> , 2009, 83, 6318-6322.	1.5	31
294	DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases. <i>Hum Vaccin</i> , 2009, 5, 623-626.	2.4	27
295	Characterization of Respiratory Syncytial Virus M- and M2-Specific CD4 T Cells in a Murine Model. <i>Journal of Virology</i> , 2009, 83, 4934-4941.	1.5	23
296	Regulatory T Cells Promote Early Influx of CD8 ⁺ T Cells in the Lungs of Respiratory Syncytial Virus-Infected Mice and Diminish Immunodominance Disparities. <i>Journal of Virology</i> , 2009, 83, 3019-3028.	1.5	120
297	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. <i>Virology</i> , 2009, 387, 414-426.	1.1	86
298	What does the report of the USMHRP Phase III study in Thailand mean for HIV and for vaccine developers?. <i>Clinical and Experimental Immunology</i> , 2009, 158, 257-259.	1.1	0
299	Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. <i>Nature Reviews Microbiology</i> , 2009, 7, 393-400.	13.6	203
300	TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. <i>Vaccine</i> , 2009, 27, 3045-3052.	1.7	51
301	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. <i>Vaccine</i> , 2008, 26, 6338-6343.	1.7	230
302	Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4 ⁺ T cells in mice immunized with respiratory syncytial virus G glycoprotein. <i>Journal of Leukocyte Biology</i> , 2008, 84, 748-759.	1.5	23
303	Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. <i>Journal of Virology</i> , 2008, 82, 2040-2055.	1.5	398
304	Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization. <i>PLoS Pathogens</i> , 2008, 4, e1000060.	2.1	158
305	A Filovirus-Unique Region of Ebola Virus Nucleoprotein Confers Aberrant Migration and Mediates Its Incorporation into Virions. <i>Journal of Virology</i> , 2008, 82, 6190-6199.	1.5	35
306	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 203-212.	0.9	101

#	ARTICLE	IF	CITATIONS
307	Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 601-605.	0.9	59
308	Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. <i>Journal of Experimental Medicine</i> , 2007, 204, 1405-1416.	4.2	428
309	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. <i>Journal of Infectious Diseases</i> , 2007, 196, 1732-1740.	1.9	175
310	Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals. <i>Vaccine</i> , 2007, 25, 1513-1525.	1.7	88
311	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. <i>Vaccine</i> , 2007, 25, 4085-4092.	1.7	134
312	Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. <i>Vaccine</i> , 2007, 25, 7737-7742.	1.7	23
313	The histopathology of fatal untreated human respiratory syncytial virus infection. <i>Modern Pathology</i> , 2007, 20, 108-119.	2.9	414
314	Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infection. <i>Virology</i> , 2007, 362, 314-319.	1.1	30
315	Smallpox vaccines: Past, present, and future. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 1320-1326.	1.5	106
316	A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. <i>Vaccine Journal</i> , 2006, 13, 1267-1277.	3.2	221
317	IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. <i>Microbes and Infection</i> , 2006, 8, 2880-2889.	1.0	24
318	Novel Approach for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 43, 304-312.	0.9	28
319	New Approaches to Vaccine Adjuvants: Inhibiting the Inhibitor. <i>PLoS Medicine</i> , 2006, 3, e57.	3.9	10
320	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector. <i>Journal of Infectious Diseases</i> , 2006, 194, 1638-1649.	1.9	283
321	Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies. <i>Journal of Virology</i> , 2006, 80, 2092-2099.	1.5	30
322	Subunit Recombinant Vaccine Protects against Monkeypox. <i>Journal of Immunology</i> , 2006, 177, 2552-2564.	0.4	139
323	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine. <i>Journal of Infectious Diseases</i> , 2006, 194, 1650-1660.	1.9	200
324	Identification of an H-2Db-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. <i>Virology</i> , 2005, 337, 335-343.	1.1	55

#	ARTICLE	IF	CITATIONS
325	Pathogenesis of Respiratory Syncytial Virus Infection in the Murine Model. Proceedings of the American Thoracic Society, 2005, 2, 110-115.	3.5	89
326	Allergen-Induced Airway Hyperresponsiveness Mediated by Cyclooxygenase Inhibition Is Not Dependent on 5-Lipoxygenase or IL-5, but Is IL-13 Dependent. Journal of Immunology, 2005, 175, 8253-8259.	0.4	21
327	RhoA Signaling Is Required for Respiratory Syncytial Virus-Induced Syncytium Formation and Filamentous Virion Morphology. Journal of Virology, 2005, 79, 5326-5336.	1.5	104
328	Lessons from Failure—Preparing for Future HIV-1 Vaccine Efficacy Trials. Journal of Infectious Diseases, 2005, 191, 647-649.	1.9	56
329	Cyclooxygenase Inhibition Augments Allergic Inflammation through CD4-Dependent, STAT6-Independent Mechanisms. Journal of Immunology, 2005, 174, 525-532.	0.4	37
330	Respiratory syncytial virus infection in the absence of STAT1 results in airway dysfunction, airway mucus, and augmented IL-17 levels. Journal of Allergy and Clinical Immunology, 2005, 116, 550-557.	1.5	108
331	Clinical Trials of DNA and Recombinant Adenovector (rAd) Vaccines for HIV. Retrovirology, 2005, 2, S61.	0.9	1
332	Respiratory Syncytial Virus in Allergic Lung Inflammation Increases Muc5ac and Gob-5. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 306-312.	2.5	111
333	Î²14 + T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV. Journal of Virology, 2004, 78, 8753-8760.	1.5	63
334	Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine. Clinical Infectious Diseases, 2004, 38, 1749-1753.	2.9	86
335	Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses. Journal of Antimicrobial Chemotherapy, 2004, 54, 299-302.	1.3	14
336	Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV. Journal of Virology, 2004, 78, 6024-6032.	1.5	77
337	RhoA-Derived Peptide Dimers Share Mechanistic Properties with Other Polyanionic Inhibitors of Respiratory Syncytial Virus (RSV), Including Disruption of Viral Attachment and Dependence on RSV G. Journal of Virology, 2004, 78, 5015-5022.	1.5	21
338	Signaling through the Prostaglandin I ₂ Receptor IP Protects against Respiratory Syncytial Virus-Induced Illness. Journal of Virology, 2004, 78, 10303-10309.	1.5	43
339	Treatment with Anti-LFA-1 Delays the CD8 + Cytotoxic-T-Lymphocyte Response and Viral Clearance in Mice with Primary Respiratory Syncytial Virus Infection. Journal of Virology, 2004, 78, 3014-3023.	1.5	28
340	Prolonged Production of TNF-Î± Exacerbates Illness during Respiratory Syncytial Virus Infection. Journal of Immunology, 2004, 173, 3408-3417.	0.4	103
341	Breakthrough Infections during Phase 1 and 2 Prime-Boost HIV-1 Vaccine Trials with Canarypox Vectors (ALVAC) and Booster Dose of Recombinant gp120 or gp160. Journal of Infectious Diseases, 2004, 190, 903-907.	1.9	38
342	Respiratory syncytial virus and other pneumoviruses: a review of the international symposium—RSV 2003. Virus Research, 2004, 106, 1-13.	1.1	21

#	ARTICLE	IF	CITATIONS
343	Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4. <i>Journal of Virology</i> , 2004, 78, 12471-12479.	1.5	25
344	Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, S46-S57.	1.1	44
345	The Complex Relationship between Respiratory Syncytial Virus and Allergy in Lung Disease. <i>Viral Immunology</i> , 2003, 16, 25-34.	0.6	26
346	IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge. <i>Journal of Immunology</i> , 2003, 170, 2037-2045.	0.4	85
347	Antiviral Activity of RhoA-Derived Peptides against Respiratory Syncytial Virus Is Dependent on Formation of Peptide Dimers. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3470-3477.	1.4	15
348	Role of Plasma Membrane Lipid Microdomains in Respiratory Syncytial Virus Filament Formation. <i>Journal of Virology</i> , 2003, 77, 1747-1756.	1.5	76
349	Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2633-2640.	1.8	276
350	Selective Cyclooxygenase-1 and -2 Inhibitors Each Increase Allergic Inflammation and Airway Hyperresponsiveness in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1154-1160.	2.5	113
351	Transgenic Overexpression of Interleukin (IL)-10 in the Lung Causes Mucus Metaplasia, Tissue Inflammation, and Airway Remodeling via IL-13-dependent and -independent Pathways. <i>Journal of Biological Chemistry</i> , 2002, 277, 35466-35474.	1.6	139
352	Clinical Trials of HIV Vaccines. <i>Annual Review of Medicine</i> , 2002, 53, 207-221.	5.0	94
353	Illness Severity, Viral Shedding, and Antibody Responses in Infants Hospitalized with Bronchiolitis Caused by Respiratory Syncytial Virus. <i>Journal of Infectious Diseases</i> , 2002, 185, 1011-1018.	1.9	125
354	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1-Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 254-261.	0.9	52
355	The Role of IFN in Respiratory Syncytial Virus Pathogenesis. <i>Journal of Immunology</i> , 2002, 168, 2944-2952.	0.4	170
356	NK T Cells Contribute to Expansion of CD8 + T Cells and Amplification of Antiviral Immune Responses to Respiratory Syncytial Virus. <i>Journal of Virology</i> , 2002, 76, 4294-4303.	1.5	155
357	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1-Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 254-261.	0.9	88
358	Augmentation of allergic inflammation by cyclooxygenase inhibition is not dependent on IL-4. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S158-S158.	1.5	0
359	Respiratory Syncytial Virus Immunobiology and Pathogenesis. <i>Virology</i> , 2002, 297, 1-7.	1.1	77
360	Viruses, dendritic cells and the lung. <i>Respiratory Research</i> , 2001, 2, 245-9.	1.4	21

#	ARTICLE	IF	CITATIONS
361	QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. <i>Vaccine</i> , 2001, 19, 2080-2091.	1.7	128
362	Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. <i>Journal of Medical Virology</i> , 2001, 63, 178-188.	2.5	78
363	RhoA Is Activated During Respiratory Syncytial Virus Infection. <i>Virology</i> , 2001, 283, 188-196.	1.1	57
364	Antiviral Activity of Lovastatin against Respiratory Syncytial Virus In Vivo and In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1231-1237.	1.4	114
365	Alternative Mechanisms of Respiratory Syncytial Virus Clearance in Perforin Knockout Mice Lead to Enhanced Disease. <i>Journal of Virology</i> , 2001, 75, 9918-9924.	1.5	61
366	Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. , 2001, 63, 178.		3
367	Hospitalization costs of respiratory syncytial virus infection. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 1100-1101.	1.1	4
368	Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. <i>Journal of General Virology</i> , 2001, 82, 2107-2116.	1.3	22
369	A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. <i>Nature Medicine</i> , 2000, 6, 35-40.	15.2	87
370	Immune-mediated disease pathogenesis in respiratory syncytial virus infection. <i>Immunopharmacology</i> , 2000, 48, 237-247.	2.0	113
371	IL-4 Diminishes Perforin-Mediated and Increases Fas Ligand-Mediated Cytotoxicity In Vivo. <i>Journal of Immunology</i> , 2000, 164, 3487-3493.	0.4	58
372	Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). <i>Journal of Medical Primatology</i> , 1999, 28, 97-104.	0.3	18
373	Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. , 1999, 57, 186-192.		108
374	Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism. <i>Journal of Virology</i> , 1999, 73, 8485-8495.	1.5	143
375	Interleukin-4 Diminishes CD8 ⁺ Respiratory Syncytial Virus-Specific Cytotoxic T-Lymphocyte Activity In Vivo. <i>Journal of Virology</i> , 1999, 73, 8944-8949.	1.5	63
376	RhoA Interacts with the Fusion Glycoprotein of Respiratory Syncytial Virus and Facilitates Virus-Induced Syncytium Formation. <i>Journal of Virology</i> , 1999, 73, 7262-7270.	1.5	74
377	Features and Outcomes of Classic Heat Stroke. <i>Annals of Internal Medicine</i> , 1999, 130, 613.	2.0	8
378	Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen. <i>Journal of Infectious Diseases</i> , 1998, 177, 301-309.	1.9	75

#	ARTICLE	IF	CITATIONS
379	Priming with Secreted Glycoprotein G of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia after RSV Challenge. <i>Journal of Virology</i> , 1998, 72, 2871-2880.	1.5	177
380	Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. <i>Vaccine</i> , 1997, 15, 597-602.	1.7	23
381	Adjuvants influence the quantitative and qualitative immune response in BALBc mice immunized with respiratory syncytial virus FG subunit vaccine. <i>Vaccine</i> , 1997, 15, 525-532.	1.7	66
382	VITAMIN A THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS INFECTION. <i>Pediatric Infectious Disease Journal</i> , 1997, 16, 84-85.	1.1	2
383	Immunological determinants of disease caused by respiratory syncytial virus. <i>Trends in Microbiology</i> , 1996, 4, 290-294.	3.5	58
384	Cytokine release and innate immunity in respiratory viral infection. <i>Seminars in Virology</i> , 1996, 7, 255-264.	4.1	14
385	Potential for Directing Appropriate Responses to Vaccines by Cytokine Manipulation. <i>BioDrugs</i> , 1996, 5, 327-333.	0.7	2
386	Protective Role of TNF- α in Respiratory Syncytial Virus Infection In Vitro and In Vivo. <i>American Journal of the Medical Sciences</i> , 1996, 311, 201-204.	0.4	4
387	Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial. <i>Annals of Internal Medicine</i> , 1996, 125, 270.	2.0	82
388	Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 683-693.	0.5	79
389	Protective Role of TNF- α in Respiratory Syncytial Virus Infection In Vitro and In Vivo. <i>American Journal of the Medical Sciences</i> , 1996, 311, 201-204.	0.4	52
390	<i>Rhodococcus equi</i> —An Increasingly Recognized Opportunistic Pathogen: Report of 12 Cases and Review of 65 Cases in the Literature. <i>American Journal of Clinical Pathology</i> , 1995, 103, 649-655.	0.4	108
391	Phase I/II Preventive Vaccine Trials: Conference Summary. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1279-1285.	0.5	13
392	Candidate AIDS Vaccines. <i>New England Journal of Medicine</i> , 1995, 333, 1331-1339.	13.9	106
393	Pathogenesis of Respiratory Syncytial Virus Vaccine-augmented Pathology. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 152, S63-S66.	2.5	92
394	Interface between Animal Models and Clinical Phase I Trials Workshop: Conference Summary. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1305-1306.	0.5	2
395	Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1713-1723.	0.5	60
396	Reply to: Vitamin A for varicella. <i>Journal of Pediatrics</i> , 1994, 125, 1018.	0.9	0

#	ARTICLE	IF	CITATIONS
397	Serum vitamin A levels in respiratory syncytial virus infection. <i>Journal of Pediatrics</i> , 1994, 124, 433-436.	0.9	59
398	Extrapulmonary Thoracic Disease Caused by <i>Blastomyces dermatitidis</i> . <i>Chest</i> , 1994, 106, 1885-1887.	0.4	5
399	Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus-Infected Mice with Respiratory Syncytial Virus-Specific Immune Serum. <i>Pediatric Research</i> , 1993, 34, 167-172.	1.1	54
400	Respiratory Syncytial Virus Infection Reinforces Reflex Apnea in Young Lambs. <i>Pediatric Research</i> , 1992, 31, 381-385.	1.1	55
401	Chronic fibrosing mediastinitis and superior vena caval obstruction from blastomycosis. <i>Annals of Thoracic Surgery</i> , 1992, 54, 764-765.	0.7	47
402	Clinical Trials of AIDS Vaccines in Seronegative Volunteers: Vectors and Combinations. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1327-1328.	0.5	1
403	Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. <i>Journal of Clinical Immunology</i> , 1992, 12, 429-439.	2.0	33
404	Reinfection of mice with respiratory syncytial virus. <i>Journal of Medical Virology</i> , 1991, 34, 7-13.	2.5	63
405	Authors' Addendum. <i>Journal of Medical Virology</i> , 1991, 35, 307-307.	2.5	0
406	VANDERBILT UNIVERSITY SCHOOL OF MEDICINE. <i>Southern Medical Journal</i> , 1989, 82, 1250-1258.	0.3	10
407	<i>Mycobacterium chelonae</i> : A cause of nodular skin lesions with a proclivity for renal transplant recipients. <i>American Journal of Medicine</i> , 1989, 86, 173-177.	0.6	80
408	Primary respiratory syncytial virus infection in mice. <i>Journal of Medical Virology</i> , 1988, 26, 153-162.	2.5	357
409	Endocarditis and Infections of Intravascular Devices Due to <i>Eikenella corrodens</i> . <i>American Journal of the Medical Sciences</i> , 1986, 292, 209-212.	0.4	36
410	Clostridial Infection of Renal Cell Carcinoma. <i>Journal of Urology</i> , 1986, 135, 354-355.	0.2	13
411	Pseudogout Presenting with Low Synovial Fluid Glucose: Identification of Crystals by Gram Stain. <i>American Journal of the Medical Sciences</i> , 1985, 289, 68-69.	0.4	4
412	Blastomycosis presenting as monoarticular arthritis. The role of synovial fluid cytology. <i>Arthritis and Rheumatism</i> , 1985, 28, 516-521.	6.7	28
413	Add-Fast Bacilli on Buffy Coat Smears in the Acquired Immunodeficiency Syndrome. <i>Southern Medical Journal</i> , 1984, 77, 246-248.	0.3	14
414	<i>Pseudomonas aeruginosa</i> Causing Osteomyelitis After Puncture Wounds of the Foot. <i>Southern Medical Journal</i> , 1984, 77, 1228-1230.	0.3	20

#	ARTICLE	IF	CITATIONS
415	Counterfeit Calculi. Southern Medical Journal, 1984, 77, 304-307.	0.3	4
416	Cancer Cellulitis. Southern Medical Journal, 1984, 77, 277-278.	0.3	5
417	Detection of Bacteremia and Fungemia: Microscopic Examination of Peripheral Blood Smears. Infection Control, 1984, 5, 448-452.	0.5	5
418	Opportunistic Infections in Endogenous Cushing's Syndrome. Annals of Internal Medicine, 1984, 101, 334.	2.0	172
419	Herpes Simplex Virus Infection of the Adult Lower Respiratory Tract. Medicine (United States), 1983, 62, 384-394.	0.4	132
420	Pericarditis Associated with Hemophilus influenzae Type B Pneumonia and Bacteremia in Two Adults. Chest, 1983, 84, 48-50.	0.4	7
421	Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses. , 0, , 559-570.		2
422	Immunization Against Viral Diseases. , 0, , 351-370.		2